|Dr. Krishna Vaddi D.V.M., Ph.D.||Founder, CEO & Director||809.88k||N/A||1966|
|Dr. Peggy A. Scherle Ph.D.||Chief Scientific Officer||564.27k||N/A||1961|
|Dr. Andrew P. Combs Ph.D.||Exec. VP & Head of Chemistry||562.46k||N/A||1966|
|Dr. Edna Huang M.D.||Pres & Chief Medical Officer||N/A||N/A||1973|
|Mr. Laurent Chardonnet||Chief Financial Officer||N/A||N/A||1965|
|Ms. Aimee Crombie Ph.D.||Sr. VP and Head of Strategic Planning & Operations||N/A||N/A||N/A|
|Dr. Madhu Pudipeddi Ph.D.||Sr. VP of Technical Operations||N/A||N/A||N/A|
|Ms. Michele Porreca M.B.A.||Chief People Officer||N/A||N/A||N/A|
|Mr. Naveen Babbar Ph.D.||Sr. VP of Translation Medicine||N/A||N/A||N/A|
|Dr. Neelesh Sharma M.D., Ph.D.||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Prelude Therapeutics Incorporated’s ISS Governance QualityScore as of October 1, 2022 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 9; Compensation: 8.